This case-control study investigated the detection of colorectal cancer (CRC) using circulating tumor DNA (ctDNA) markers up to two years before clinical diagnosis. Methylated ctDNA markers were analyzed in plasma samples from 106 CRC patients and 106 healthy controls. A panel of eight markers (BMP3, FLT1, IKZF1, SFRP1, SFRP2, NPTX2, SLCA1, and VIM) achieved 43% sensitivity and 86% specificity for CRC detection up to two years prior to diagnosis. These findings were reproducible in an independent validation set, suggesting the potential for earlier CRC diagnosis using ctDNA detection as part of screening programs.
Publisher
British Journal of Cancer
Published On
Jul 27, 2023
Authors
Siv S. Brenne, Poul Henning Madsen, Inge Søkilde Pedersen, Kristian Hveem, Frank Skorpen, Henrik Bysum Kaurup, Guro F. Giskeødegård, Eivor A. Lausgård
